PL1843746T3 - Formulacje analogów somatostatyny - Google Patents

Formulacje analogów somatostatyny

Info

Publication number
PL1843746T3
PL1843746T3 PL05818366T PL05818366T PL1843746T3 PL 1843746 T3 PL1843746 T3 PL 1843746T3 PL 05818366 T PL05818366 T PL 05818366T PL 05818366 T PL05818366 T PL 05818366T PL 1843746 T3 PL1843746 T3 PL 1843746T3
Authority
PL
Poland
Prior art keywords
somatostatin analogue
analogue formulations
formulations
somatostatin
analogue
Prior art date
Application number
PL05818366T
Other languages
English (en)
Polish (pl)
Inventor
Fredrik Joabsson
Markus Johnsson
Andreas Norlin
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500807A external-priority patent/GB0500807D0/en
Priority claimed from GB0507811A external-priority patent/GB0507811D0/en
Priority claimed from PCT/GB2005/002217 external-priority patent/WO2005117830A1/fr
Priority claimed from GB0518878A external-priority patent/GB0518878D0/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PL1843746T3 publication Critical patent/PL1843746T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL05818366T 2005-01-14 2005-12-09 Formulacje analogów somatostatyny PL1843746T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0500807A GB0500807D0 (en) 2005-01-14 2005-01-14 Formulation
GB0507811A GB0507811D0 (en) 2005-04-18 2005-04-18 Formulation
PCT/GB2005/002217 WO2005117830A1 (fr) 2004-06-04 2005-06-06 Formulations de depot lipidique
GB0518878A GB0518878D0 (en) 2005-09-15 2005-09-15 Formulations
EP05818366A EP1843746B1 (fr) 2005-01-14 2005-12-09 Formulations à base d'analogues de somatostatine
PCT/GB2005/004748 WO2006075124A1 (fr) 2005-01-14 2005-12-09 Formulations à base d'analogues de somatostatine

Publications (1)

Publication Number Publication Date
PL1843746T3 true PL1843746T3 (pl) 2011-09-30

Family

ID=35986077

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05818366T PL1843746T3 (pl) 2005-01-14 2005-12-09 Formulacje analogów somatostatyny

Country Status (7)

Country Link
EP (1) EP1843746B1 (fr)
JP (1) JP5171262B2 (fr)
KR (1) KR100983746B1 (fr)
AU (1) AU2005324794C1 (fr)
CA (1) CA2594711C (fr)
PL (1) PL1843746T3 (fr)
WO (1) WO2006075124A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
US8920782B2 (en) 2005-01-14 2014-12-30 Camurus Ab Topical bioadhesive formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US9060935B2 (en) 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
AU2015227534B2 (en) * 2007-06-15 2017-02-23 Camurus Ab Peptide slow-release formulations
AU2012202338B2 (en) * 2007-06-15 2015-07-09 Camurus Ab Peptide slow-release formulations
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
ES2528409T3 (es) * 2007-10-24 2015-02-10 Camurus Ab Formulaciones de liberación controlada
KR100998175B1 (ko) 2008-05-30 2010-12-03 애니젠 주식회사 소마토스타틴의 제조방법
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
CA2755436C (fr) 2009-03-19 2019-10-29 Claude Carelli Peptides destines a inhiber l'igf-1
US11433120B2 (en) 2011-05-25 2022-09-06 Camurus Ab Controlled release peptide formulations
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
SI2787974T1 (sl) * 2011-12-05 2017-10-30 Camurus Ab Robustno kontrolirano-sproščujoče peptidne formulacije
SG10201606271RA (en) * 2012-01-31 2016-09-29 Santen Pharmaceutical Co Ltd Non-aqueous liquid composition
AU2013265210B2 (en) * 2012-05-25 2016-09-15 Camurus Ab Somatostatin receptor agonist formulations
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP2823808A1 (fr) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Composition pharmaceutique de lanréotide à libération prolongée
AU2017336199B2 (en) 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
EP3421485A1 (fr) 2017-06-30 2019-01-02 Université de Strasbourg Anticorps pour la prévention et le traitement de la thrombose
EP3437651A1 (fr) 2017-08-03 2019-02-06 Université de Strasbourg Peptides pour le traitement et la prévention de la stéatose hépatique non alcoolique
CN116854779A (zh) 2017-12-14 2023-10-10 斯特拉斯堡大学 用于治疗和预防非酒精性脂肪肝病和纤维化的肽
PT3897697T (pt) 2018-12-21 2023-06-27 Univ Strasbourg Péptidos para o tratamento e a prevenção de diabetes e distúrbios associados
JP2021059680A (ja) * 2019-10-08 2021-04-15 花王株式会社 液晶組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5531925A (en) * 1991-10-04 1996-07-02 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
WO1993006921A1 (fr) * 1991-10-04 1993-04-15 Gs Biochem Ab Particules, procede de preparation desdites particules et utilisations
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
WO1997013528A1 (fr) * 1995-10-12 1997-04-17 Gs Development Ab Composition pharmaceutique pour l'administration d'un principe actif sur ou au travers d'une surface cutanee ou muqueuse
JP2001524958A (ja) * 1997-04-17 2001-12-04 ジーエス ディベロップメント アクティエボラーグ 新規な液晶をベースとする生物接着性薬剤送出系
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
WO2005046642A1 (fr) * 2003-11-07 2005-05-26 Camurus Ab Compositions de lipides et de peptides cationiques
DE602005025083D1 (fr) * 2004-01-23 2011-01-13 Camurus Ab

Also Published As

Publication number Publication date
KR100983746B1 (ko) 2010-09-24
CA2594711C (fr) 2012-11-06
JP2008526933A (ja) 2008-07-24
KR20070104599A (ko) 2007-10-26
EP1843746B1 (fr) 2011-03-16
JP5171262B2 (ja) 2013-03-27
WO2006075124A1 (fr) 2006-07-20
CA2594711A1 (fr) 2006-07-20
AU2005324794C1 (en) 2010-12-02
AU2005324794A1 (en) 2006-07-20
EP1843746A1 (fr) 2007-10-17
AU2005324794B2 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
PL1843746T3 (pl) Formulacje analogów somatostatyny
PL1888031T3 (pl) Preparaty analogu glp-1
GB2424581B (en) Formulations
PL1845942T3 (pl) Preparaty analogu GnRH
EP1909584A4 (fr) Formulations a base de prenylflavonoides
GB0505569D0 (en) Formulations
GB0526419D0 (en) Formulation
EP1951693A4 (fr) Formulations solides
GB0517673D0 (en) Formulation
GB0501030D0 (en) Formulation
IL187732A0 (en) Levodopa compositions
LT1928232T (lt) Kieta kompozicija
GB0523634D0 (en) Solid cleaning formulations
GB0522917D0 (en) Formulations
GB0518878D0 (en) Formulations
GB0520388D0 (en) Formulations
GB0526322D0 (en) Formulations
GB0519090D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations
GB0500917D0 (en) Novel formulations
GB0500915D0 (en) Novel formulations
GB0500913D0 (en) Novel formulations
GB0500912D0 (en) Novel formulations
GB0504106D0 (en) Novel formulations
IL179208A0 (en) Intereferon formulations